Priothera

Priothera is a private, clinical-stage biotech developing mocravimod, a sphingosine-1-phosphate (S1P) receptor modulator, to improve outcomes in blood cancer patients undergoing stem cell transplants. The company's core innovation is a potential best-in-class therapy designed to decouple the beneficial graft-versus-leukemia (GvL) effect from the harmful graft-versus-host disease (GvHD), addressing a major unmet need in acute myeloid leukemia (AML) and other hematological malignancies. With promising early clinical data, Priothera is advancing its lead program into a pivotal Phase 3 study (MO-TRANS) for AML patients post-transplant, positioning itself to transform the standard of care in a high-mortality setting. The company is led by a seasoned team with deep experience in immunology and drug development.

Sphingosine-1-phosphate (S1P) receptor modulation platform designed to sequester lymphocytes in lymphoid organs and bone marrow, aiming to decouple graft-versus-leukemia (GvL) effects from graft-versus-host disease (GvHD) in cell-based therapies.

The post-transplant maintenance space in AML is relatively uncrowded with no approved standard, giving Priothera a first-mover opportunity. However, competition exists from other investigational agents (e.g., FLT3 inhibitors, hypomethylating agents) and from evolving transplant protocols. In the broader S1P modulator space, drugs like ozanimod exist but are not developed for this specific oncology/transplant indication.